https://pubmed.ncbi.nlm.nih.gov/37371763/ Storage disorders
Review

Biomedicines. 2023 Jun 8;11(6):1668.
doi: 10.3390/biomedicines11061668.

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland

Zbigniew Żuber 1, Beata Kieć-Wilk 2, Łukasz Kałużny 3, Jolanta Wierzba 4, Anna Tylki-Szymańska 5

Abstract
Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is a rare, inherited lysosomal storage disease. The disease is caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase (I2S) due to mutations in the IDS gene, which leads to accumulation of glycosaminoglycans (GAGs). Deficiency of I2S enzyme activity in patients with MPS II leads to progressive lysosomal storage of GAGs in the liver, spleen, heart, bones, joints, and respiratory tract. This process disturbs cellular functioning and leads to multisystemic disease manifestations. Symptoms and their time of onset differ among patients. Diagnosis of MPS II involves assessment of clinical features, biochemical parameters, and molecular characteristics. Life-long enzyme replacement therapy with idursulfase (recombinant human I2S) is the current standard of care. However, an interdisciplinary team of specialists is required to monitor and assess the patient's condition to ensure optimal care. An increasing number of patients with this rare disease reach adulthood and old age. The transition from pediatric care to the adult healthcare system should be planned and carried out according to guidelines to ensure maximum benefit for the patient.